Newsroom

Cambridge neighbors, NIBR and Harvard, further disrupt technology. Read how their alliance is accelerating drug discovery.

The majority of Europeans can’t identify the warning signs of heart failure, a life threatening disease, which affects one in five people in the region.

Novartis researchers use automation to rapidly identify starting points for new drugs.

Heart failure affects 26 million people worldwide. More people die from heart failure than from some advanced cancers, including breast and bowel cancer.

Ahead of World Malaria Day, Novartis and Malaria No More delivered 2 million pediatric antimalarials to Zambia provided through the Power of One campaign.

Up the stairs to the entrance of the plane they climb: small children with cloudy eyes, teens with thick glasses and practiced squints, adults with dark shades.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

Patients with glaucoma, which affects 60 million people worldwide, can lose up to 40 percent of their sight before they begin to notice any change in vision.

Raising a child with a rare disease can feel overwhelming and isolating, but many parents end up being extremely proud of their children’s achievements.

Parents and doctors can help children understand rare diseases like TSC and SJIA with the help of cartoon dogs and comic book superheroes.

After 40 years of working in information technology, Jim Barrington took a partial retirement from his job as Novartis’ chief information officer and started looking for new ways to apply his skills.

With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.